<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Procalcitonin use in lower respiratory tract infections</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Procalcitonin use in lower respiratory tract infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Procalcitonin use in lower respiratory tract infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Chanu Rhee, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael K Mansour, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julio A Ramirez, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3970841813"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Procalcitonin is a serum biomarker that helps distinguish bacterial infection from other causes of infection or inflammation. In patients with lower respiratory tract infections, procalcitonin can serve as a helpful adjunct to clinical judgment for guiding antibiotic therapy and resolving diagnostic uncertainty. The study of procalcitonin is evolving, and the approach to procalcitonin use varies among institutions and experts.</p><p>This topic reviews the role of procalcitonin in the evaluation and management of adults with lower respiratory tract infections, including pneumonia, acute bronchitis, and acute exacerbations of chronic obstructive pulmonary disease.</p><p>The general evaluation and management of lower respiratory tract infections are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a> and  <a class="medical medical_review" href="/z/d/html/6870.html" rel="external">"Acute bronchitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/108592.html" rel="external">"Evaluation for infection in exacerbations of chronic obstructive pulmonary disease"</a> and  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a> and  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting", section on 'General approach'</a>.)</p><p class="headingAnchor" id="H68080152"><span class="h1">RATIONALE FOR USE</span><span class="headingEndMark"> — </span>Reducing antibiotic use for the treatment of respiratory tract infections is a global health care priority [<a href="#rid1">1-6</a>]. Lower respiratory tract infections (LRTIs) are among the most common reasons for antibiotic prescription [<a href="#rid7">7</a>]. An estimated 30 to 85 percent of these prescriptions are unnecessary or inappropriate [<a href="#rid8">8-16</a>]. Even when indicated, antibiotic treatment courses often exceed recommended durations [<a href="#rid16">16</a>].</p><p>Antibiotic overuse for LRTIs is in part due to the difficulty in distinguishing between viral and bacterial infections. A substantial fraction of LRTIs are viral [<a href="#rid17">17-23</a>] and do not require treatment with antibiotics. However, clinical signs and symptoms of bacterial and viral LRTIs are similar and often cannot be distinguished based on clinical features alone. Microbiologic testing can be helpful, but results from culture or other assays often take days to obtain and, in many cases, a pathogen is not identified. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Microbiologic testing'</a>.)</p><p>Procalcitonin has good discriminatory value for distinguishing between viral and bacterial infections, and results can be obtained in hours or less. In patients with community-acquired pneumonia, procalcitonin is about 65 to 70 percent accurate in distinguishing bacterial from viral pathogens [<a href="#rid24">24</a>]. When used as part of an algorithm in combination with clinical judgment in patients with LRTIs, procalcitonin has been shown in some studies to reduce unnecessary antibiotic use by about 25 to 50 percent without increasing morbidity or mortality [<a href="#rid25">25-29</a>].</p><p class="headingAnchor" id="H1078093238"><span class="h1">PROCALCITONIN BIOLOGY</span></p><p class="headingAnchor" id="H3089252941"><span class="h2">Synthesis</span><span class="headingEndMark"> — </span>Procalcitonin synthesis pathways vary in different inflammatory states. In the absence of systemic inflammation, procalcitonin synthesis is restricted to thyroid neuroendocrine cells, and the protein is not released into the blood until it is cleaved into its mature form, calcitonin [<a href="#rid30">30-33</a>]. Thus, serum procalcitonin is typically undetectable in healthy persons when standard assays are used [<a href="#rid32">32</a>].</p><p>When systemic inflammation is caused by bacterial infection, procalcitonin synthesis is induced in nearly all tissues and released into the blood. Known triggers for synthesis include bacterial toxins, such as endotoxin [<a href="#rid34">34</a>], and cytokines including tumor necrosis factor (TNF)-alpha, interleukin-1-beta, and interleukin-6 [<a href="#rid30">30,35,36</a>]. In contrast, procalcitonin synthesis is not induced in most viral infections [<a href="#rid30">30-33</a>]. The lack of induction is likely due to cytokines released in viral infections that inhibit TNF-alpha production, such as interferon-gamma [<a href="#rid31">31,33,35-39</a>].</p><p>Not all bacterial infections cause procalcitonin to rise, or rise to the same degree. Typical bacteria, such as <em>Streptococcus pneumoniae</em> or <em>Haemophilus influenzae</em>, tend to cause greater rises in procalcitonin than atypical bacteria [<a href="#rid24">24,40,41</a>]. Certain fungi, such as <em>Pneumocystis jirovecii</em> [<a href="#rid42">42,43</a>] and <em>Candida</em> species [<a href="#rid44">44-46</a>], and parasites, such as malaria [<a href="#rid47">47,48</a>], have also been reported to cause elevations in procalcitonin.</p><p>Noninfectious causes of systemic inflammation, such as shock, trauma, surgery, burn injury, and chronic kidney disease can also induce procalcitonin production but are less closely correlated with procalcitonin induction than bacterial infection [<a href="#rid39">39,49</a>]. A number of other causes of elevated procalcitonin levels have been reported.</p><p class="headingAnchor" id="H3267794352"><span class="h2">Kinetics</span><span class="headingEndMark"> — </span>Serum procalcitonin levels rise within two to four hours of an inflammatory stimulus, typically peaking within 24 to 48 hours [<a href="#rid39">39,50</a>]. Peak levels roughly correlate with the severity of infection, with higher levels observed in patients with septic shock and sepsis than with uncomplicated pneumonia or other localized infections [<a href="#rid50">50-52</a>].</p><p>With resolution of inflammation, procalcitonin levels quickly decline at a predictable rate. After reaching peak, levels decline by about 50 percent every 1 to 1.5 days [<a href="#rid50">50</a>]. When the inflammatory stimulus is ongoing, procalcitonin production continues and levels plateau [<a href="#rid50">50</a>]. These kinetics are altered in patients with renal dysfunction. (See <a class="local">'Chronic kidney disease'</a> below.)</p><p class="headingAnchor" id="H170222989"><span class="h1">CLINICAL USE</span><span class="headingEndMark"> — </span>Procalcitonin can serve as a helpful adjunct to clinical judgment for guiding antibiotic therapy and resolving diagnostic uncertainty in patients with known or suspected lower respiratory tract infections (LRTIs). However, the study of procalcitonin is evolving, the approach to procalcitonin use varies among experts, and the assay is not available at all institutions.</p><p>Procalcitonin's greatest utility may be for guiding early antibiotic discontinuation in patients with community-acquired pneumonia (CAP). Discontinuation of antibiotics based on defined procalcitonin thresholds has been shown in some studies to reduce antibiotic use without adverse outcomes  (<a class="graphic graphic_algorithm graphicRef117052" href="/z/d/graphic/117052.html" rel="external">algorithm 1</a>) [<a href="#rid27">27,28</a>]. In most other circumstances, however, we interpret procalcitonin levels qualitatively (eg, as high, low, rising, or falling)  (<a class="graphic graphic_table graphicRef117054" href="/z/d/graphic/117054.html" rel="external">table 1</a>), weighting its value similarly to other clinical findings.</p><p>In all circumstances, clinicians should also be aware of the limitations of the assay, including noninfectious factors that cause procalcitonin to rise or fall, how procalcitonin levels vary among pathogens, and patient populations in which procalcitonin has not been well studied (see <a class="local">'Limitations'</a> below). All decisions to stop antibiotics should be made in combination with clinical judgment, noting that certain infections require prolonged duration of antibiotics regardless of procalcitonin levels (eg, CAP complicated by <em>Staphylococcus aureus </em>bacteremia).</p><p class="headingAnchor" id="H2885809482"><span class="h2">Guiding antibiotic therapy</span></p><p class="headingAnchor" id="H3117849100"><span class="h3">Community-acquired pneumonia in hospitalized patients</span><span class="headingEndMark"> — </span>We measure procalcitonin to help determine when to discontinue antibiotic therapy in immunocompetent patients who are hospitalized with known or suspected CAP. We generally obtain a procalcitonin level at the time of diagnosis and repeat the level every one to two days, depending on severity of illness. We determine the need for continued antibiotic therapy based on the patient's clinical course, suspected etiology, serial procalcitonin levels, and microbiologic tests results.</p><p>We do not typically use procalcitonin to inform antibiotic initiation in patients with known or suspected CAP.</p><p class="bulletIndent1"><span class="glyph">●</span>In critically ill patients, empiric antibiotic therapy should never be delayed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although most clinically stable patients with suspected CAP should also receive empiric antibiotic therapy, some experts withhold antibiotics in selected low-risk patients with very low procalcitonin levels when a viral cause is suspected and close follow-up is arranged.</p><p></p><p>Our approach is based on a large body of evidence that supports the use of procalcitonin for guiding antibiotic decision making [<a href="#rid27">27-29,53-57</a>]. In a patient-level meta-analysis comparing a procalcitonin algorithm with standard care in over 6000 patients with LRTIs of any kind, there was a substantial reduction in antibiotic use without increasing adverse outcomes in the procalcitonin group [<a href="#rid29">29,57</a>]. In an analysis of a subset of 2910 patients with CAP, the procalcitonin algorithm reduced antibiotic exposure by 2.9 days when compared with standard care (7.5 versus 10.4 days, 95% CI -2.02 to -2.87). There were no significant differences in mortality, treatment failure, length of stay, or antibiotic-associated side effects. Consistent results were found across treatment settings (eg, primary care, emergency department, and intensive care unit [ICU]) and in trials that had high (&gt;70 percent) or low adherence to the procalcitonin algorithm. When procalcitonin algorithms are used, the greatest reduction in antibiotic use comes from earlier antibiotic discontinuation rather than curtailing antibiotic initiation [<a href="#rid29">29,57</a>].</p><p>Our approach is similar to the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) guidelines, which do not recommend procalcitonin to guide initiation or withholding of antibiotic therapy for patients with CAP. The guidelines suggest that serial procalcitonin measurement may be most useful in settings where the average length of stay for patients with CAP exceeds five to seven days [<a href="#rid58">58</a>]. The guidelines also suggest that a low procalcitonin level can help guide early antibiotic discontinuation in a patient who has achieved early clinical stability, has a positive test for influenza, and no evidence of bacterial infection. In our experience, this also applies to other respiratory viruses. </p><p class="headingAnchor" id="H2347977315"><span class="h4">Clinically stable patients</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic discontinuation</strong> – We use the following procalcitonin thresholds, along with clinical judgment, to help guide antibiotic discontinuation in clinically stable patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with procalcitonin levels that are persistently &lt;0.25 ng/mL in whom the initial diagnosis of CAP was uncertain and an alternative diagnosis has been made (eg, congestive heart failure), we generally discontinue antibiotics.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with procalcitonin levels &lt;0.25 ng/mL with probable viral CAP or a noninfectious syndrome (based on history or test results), we generally discontinue antibiotics. Low procalcitonin levels suggest that concurrent bacterial infection is improbable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with known or suspected bacterial CAP who have received at least five days of appropriate antibiotic therapy, we consider discontinuing antibiotics for patients who have improved clinically and who have a procalcitonin level &lt;0.25 ng/mL (or a ≥80 percent drop from peak level). However, reaching a level of &lt;0.25 ng/mL is not a requirement for antibiotic discontinuation; clinical judgment alone is adequate in patients with clinically resolved pneumonia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with known or suspected bacterial CAP with procalcitonin levels that are declining but still ≥0.25 ng/mL, we generally continue antibiotic therapy. Declining procalcitonin levels suggest response to antibiotic therapy. However, as noted above, reaching a level of &lt;0.25 ng/mL (or a ≥80 percent drop from peak level) is not a requirement for antibiotic discontinuation; clinical judgment alone is adequate in patients with clinically resolved pneumonia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with rising levels, or levels that fail to decline with antibiotic therapy, we consider other causes of elevated procalcitonin levels and assess whether to continue or change antibiotic regimens based on the individual patient characteristics (see <a class="local">'Limitations'</a> below). In patients who are not clinically improving and have known or suspected bacterial CAP, persistently high or rising procalcitonin levels suggest poorer prognosis or uncontrolled infection.</p><p></p><p class="bulletIndent1">Optimal thresholds for discontinuing antibiotics have not been precisely determined. Some experts use a lower threshold, typically 0.1 ng/mL, when deciding to discontinue antibiotics. Others take into account the rate of decline and discontinue antibiotics when the procalcitonin level has decreased by ≥80 percent from its peak. The latter approach is most often used when initial values are &gt;5 ng/mL and the time period it would take to decline to &lt;0.25 ng/mL would exceed a reasonable duration of antibiotics [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">The procalcitonin thresholds evaluated in most trials (and outlined above) are derived from the procalcitonin-guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections (ProHOSP) study [<a href="#rid28">28</a>]. In this trial, 1359 adults with an LRTI of any kind were randomized to procalcitonin-guided antibiotic management or standard care. Clinicians were allowed to overrule the procalcitonin algorithm and start antibiotics in patients with respiratory or hemodynamic instability, with pneumonia due to <em>Legionella pneumophila, </em>or with other risk factors for poor outcomes regardless of the procalcitonin level. Among the 925 patients with CAP, mean antibiotic exposure was reduced by 30 percent (95% CI -37.6 to -26.9) with no difference in adverse events. Clinician adherence to the algorithm was about 90 percent.</p><p></p><p class="bulletIndent1">In contrast, the more recent United States-based ProACT Trial, which enrolled patients presenting to the emergency department with any suspected lower respiratory tract infection, including CAP, and used the same algorithm as ProHOSP, did not show reduction in antibiotic utilization [<a href="#rid60">60</a>]. This may be a result of increased provider knowledge about appropriate antibiotic prescribing and shorter baseline treatment courses in hospitals with antibiotic stewardship programs and high adherence to pneumonia quality measures. (See <a class="local">'Practical considerations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic initiation</strong> – Although most procalcitonin algorithms provide an option for withholding antibiotics at the time of diagnosis, using procalcitonin to determine whether to start antibiotics is more controversial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with known or suspected CAP, we treat with empiric antibiotics regardless of the initial procalcitonin level because of the high morbidity associated with CAP and the imperfect diagnostic accuracy of procalcitonin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For selected clinically stable patients without comorbidities, some experts consider withholding antibiotics when the clinical presentation and/or laboratory results strongly suggest a viral infection (or if suspicion of bacterial infection is otherwise low) and the procalcitonin level is &lt;0.25. The decision to withhold antibiotics should also take into account the patient's severity of illness and the degree of suspicion for bacterial CAP [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent2">If antibiotics are withheld and the patient is hospitalized, a repeat procalcitonin can be checked within 6 to 24 hours to ensure that the initial procalcitonin was not drawn too early in the course of the patient's illness.</p><p></p><p class="bulletIndent1">In patients with CAP, procalcitonin is about 65 to 70 percent accurate in distinguishing bacterial from viral pathogens [<a href="#rid24">24,61</a>]. In addition, the optimal threshold for diagnosing bacterial pneumonia has not been determined [<a href="#rid62">62-64</a>]. Because the assay's predictive value is augmented when used in combination with clinical judgment and other test results, such as viral respiratory panels [<a href="#rid65">65</a>], we withhold antibiotics only if other factors strongly suggest a nonbacterial etiology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Procalcitonin also has prognostic value in patients with CAP [<a href="#rid51">51,66-70</a>]. In a patient-level meta-analysis of 14 trials and 4211 patients with respiratory tract infection, initially elevated procalcitonin levels were associated with an increased risk of treatment failure (odds ratio [OR] 1.66, 95% CI 1.44-1.90) and mortality (OR 1.69, 95% CI 1.41-2.04) in patients with CAP. However, the optimal threshold for predicting adverse events has not been determined. Serial procalcitonin levels may be more predictive than single values. Several cohort studies suggest that rising levels predict mortality and other adverse outcomes, either independently [<a href="#rid67">67</a>] or in combination with disease severity scores [<a href="#rid68">68,69</a>]. Thus, when procalcitonin levels fail to decline with antibiotic therapy, we generally reevaluate our diagnostic and therapeutic approach [<a href="#rid51">51,61-63,66-72</a>].</p><p></p><p>Additional detail on the evaluation and management of CAP is provided separately. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p class="headingAnchor" id="H851682355"><span class="h4">Critically ill patients</span><span class="headingEndMark"> — </span>We also use procalcitonin when considering early antibiotic discontinuation in patients with CAP who were septic or critically ill at the time of diagnosis. The thresholds that we use to guide antibiotic discontinuation differ in critically ill than stable patients. We consider stopping antibiotics when procalcitonin levels fall below 0.5 ng/mL (or decrease by ≥80 percent from peak if initial value &gt;5 ng/mL). The procalcitonin threshold used to stop antibiotics in most trials evaluating the critically ill is higher (0.5 ng/mL) than that used for stable patients with respiratory tract infections (0.25 ng/mL), presumably because baseline levels for critically ill patients are expected to be abnormal. Other experts, including some UpToDate authors, use a lower threshold, typically 0.25 ng/mL, for antibiotic discontinuation [<a href="#rid73">73</a>].</p><p>We do not use procalcitonin to inform antibiotic initiation in this population. In any patient with known or suspected CAP who is septic or critically ill, antibiotics should not be delayed regardless of the initial procalcitonin level.</p><p>The recommendations are based on randomized trials evaluating procalcitonin in the critically ill [<a href="#rid55">55,74-79</a>] and on the body of evidence that supports the use of procalcitonin for guiding antibiotic use in patients with LRTIs in general [<a href="#rid28">28,29</a>]. As an example, in a patient-level meta-analysis evaluating over 2400 patients admitted to the intensive care unit with LRTI of any kind, procalcitonin-guided antibiotic decision making was associated with 1.23 day reduction in antibiotic duration (8.8 versus 9.5 days, 95% CI 0.82 to -0.65) when compared with placebo [<a href="#rid28">28,29</a>]. There were no significant differences in mortality, treatment failure, length of stay, or antibiotic-associated side effects. Validation of these findings in the broader clinical settings outside of randomized trials is limited.</p><p>The algorithm we use to manage patients who are critically ill is derived from the Stop Antibiotics on Procalcitonin guidance Study (SAPS) trial, which evaluated 1575 patients admitted to the ICU with suspected or known infection (65 percent had a respiratory tract infection) [<a href="#rid74">74</a>]. Procalcitonin levels were checked daily, and clinicians were advised to stop antibiotics when levels were ≤0.5 ng/mL or if the level decreased by ≥80 percent from peak. Compared with controls, the procalcitonin group had significantly lower median antibiotic exposure (7.5 versus 9.3 defined daily doses) and lower 28-day mortality (19.6 versus 25 percent). Clinician adherence to the algorithm within 48 hours was 53 percent; the main reason for nonadherence was concern about stopping antibiotics in patients who were not yet clinically stable. Identical thresholds of ≤0.5 ng/mL or ≥80 percent reduction from peak on day 5 were used in the Procalcitonin-Guided Antimicrobial Therapy to Reduce Long-Term Sequelae of Infections (PROGRESS) trial, which evaluated 266 patients with sepsis (over 60 percent from pneumonia). Compared with usual care, procalcitonin-guided antibiotic discontinuation had lower antibiotic exposure (median 5 versus 10 days) and lower rates of infection-related adverse events at 180 days and 28-day mortality [<a href="#rid80">80</a>].  </p><p>Our recommendations are largely consistent with the 2021 Surviving Sepsis Campaign and the 2016 IDSA antimicrobial stewardship guidelines, which both give a weak recommendation for using serial procalcitonin levels to guide antibiotic discontinuation in patients with suspected infections in the ICU [<a href="#rid81">81,82</a>].</p><p>Additional detail on the evaluation and management of CAP in patients who are critically ill is provided separately. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a> and  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H1300026748"><span class="h3">Other lower respiratory tract infections</span></p><p class="headingAnchor" id="H1532991425"><span class="h4">Community-acquired pneumonia in outpatients</span><span class="headingEndMark"> — </span>The approach to using procalcitonin levels to guide antibiotic-decision making for outpatients with CAP varies among experts. When the test is available and turnaround time is quick, some experts use procalcitonin in conjunction with a positive test for a viral pathogen (eg, influenza) to withhold antibiotics or stop them early, provided that there are no other signs of bacterial infection (eg, dense consolidation on chest imaging, markedly high white blood cell count, or positive microbiologic test) and that patient has close follow-up. </p><p>Other experts prefer to treat empirically with antibiotics because bacterial CAP is hard to exclude definitively, the morbidity association with CAP is high, and outpatient treatment courses for CAP are short (eg, five days). </p><p>While data directly supporting procalcitonin-guided antibiotic decision-making in outpatients with CAP are limited, one randomized trial comparing &gt;150 outpatients with CAP found that clinical outcomes were similar and antibiotic exposure was decreased when procalcitonin was used [<a href="#rid54">54</a>]. This approach is further supported by a larger trial evaluating &gt;450 patients with any LRTI (including CAP, though the proportion of patient with CAP is not known); clinical outcomes were similar and antibiotic exposure was reduced when procalcitonin values were used to guide antibiotic decision-making [<a href="#rid83">83</a>]. </p><p class="headingAnchor" id="H2543084456"><span class="h4">Ventilator-associated pneumonia</span><span class="headingEndMark"> — </span>The utility of procalcitonin for guiding antibiotic therapy in patients with ventilator-associated pneumonia (VAP) is less certain than for CAP. Because patients with VAP are often critically ill, we typically start antibiotics when the diagnosis is suspected, regardless of the procalcitonin level. This recommendation is derived from observational data that suggest that procalcitonin has poor predictive value for the diagnosis of VAP [<a href="#rid84">84,85</a>].</p><p>For patients with known or suspected VAP, we use procalcitonin to help determine when to discontinue antibiotic therapy. The optimal threshold for guiding antibiotic discontinuation in patients with VAP has not been determined. When interpreting results, we generally consider procalcitonin levels qualitatively (eg, as high, low, rising, or falling) and in conjunction with other clinical parameters  (<a class="graphic graphic_table graphicRef117054" href="/z/d/graphic/117054.html" rel="external">table 1</a>) [<a href="#rid84">84-87</a>].</p><p>A single randomized trial (ProVAP) directly evaluated use of procalcitonin algorithms versus standard care in 101 patients with known or suspected VAP. In the procalcitonin group, stopping antibiotics when the procalcitonin level was &lt;0.5 ng/mL or had decreased by ≥80 percent from peak resulted in a significant 27 percent reduction in antibiotic use (median 10 versus 15 days) without increasing adverse outcomes. While similar findings have been observed in subgroup analyses of patients with VAP in larger randomized trials evaluating procalcitonin use in critically ill patients, less than 400 patients have been studied overall [<a href="#rid29">29,55,57,75,76,88</a>].</p><p>Our approach is consistent with the 2016 IDSA and ATS guidelines, which strongly recommend using clinical criteria alone, rather than procalcitonin plus clinical criteria, to decide whether to start antibiotics [<a href="#rid89">89</a>]. These guidelines also make a weak recommendation for using procalcitonin in addition to clinical criteria when discontinuing antibiotics. The 2017 combined European and Latin American (European Respiratory Society, European Society of Intensive Care Medicine, European Society of Clinical Microbiology and Infectious Diseases, and Asociación Latinoamericana del Tórax) guidelines do not recommend procalcitonin use in patients with VAP when the anticipated antibiotic course is 7 to 8 days but do recommend use in selected cases when care needs to be individualized (eg, patients on toxic or second-line agents such as <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> or those infected with highly drug resistant pathogens) [<a href="#rid90">90</a>].</p><p>Additional detail on the evaluation and management of hospital-acquired and ventilator-associated pneumonia is provided separately. (See  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.) </p><p class="headingAnchor" id="H571937569"><span class="h4">Acute exacerbations of chronic obstructive pulmonary disease</span><span class="headingEndMark"> — </span>Use of procalcitonin to help guide antibiotic therapy in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is controversial. The clinical utility and safety of using procalcitonin for this patient population is not firmly established. However, a substantial fraction of acute COPD exacerbations are caused by viruses, and some experts use procalcitonin to help guide antibiotic discontinuation in patients with nonsevere AECOPD, particularly at institutions where comprehensive molecular respiratory viral panels are available.</p><p>While procalcitonin use in patients hospitalized with AECOPD has been shown to reduce antibiotic exposure without increasing adverse events in several trials [<a href="#rid29">29,91-96</a>], this benefit has not been consistently demonstrated in all trials and treatment settings [<a href="#rid97">97</a>]. In addition, the studied population is small overall and most trials have methodologic limitations. In one trial comparing procalcitonin algorithms with guideline-concordant care in 208 patients with AECOPD in the emergency department, algorithm use reduced antibiotic exposure by 30 percent without increasing adverse events, including the need for subsequent antibiotic use over the next six months (relative risk [RR] 0.56, 95% CI 0.43-0.73) [<a href="#rid92">92</a>]. In this trial, procalcitonin levels were low at admission in the majority of patients (median 0.096 ng/mL; interquartile range 0.070 to 0.200), which is consistent with epidemiologic data showing that most AECOPD are caused by viruses [<a href="#rid22">22</a>]. Median procalcitonin levels did not differ with the AECOPD severity, suggesting that bacterial infections may not be more prevalent in severe exacerbations. In a noninferiority trial, 302 patients admitted to the ICU with severe AECOPDs and suspected LRTI were randomized to procalcitonin-guided antibiotic initiation and discontinuation versus guideline-concordant care [<a href="#rid97">97</a>]. There were no significant differences in baseline characteristics, procalcitonin levels, or microbiologic findings between groups. However, short-term mortality was higher in patients who received procalcitonin-guided care (20 versus 14 percent; adjusted difference [AD] 6.6 percent, 90% CI -0.3 to 13.5). The mortality difference was highest in the subgroup of 119 patients who did not receive antibiotics at initial presentation (31 versus 12 percent; AD 19.2 percent, 90% CI 7.2-31.1) but not detectable among the 182 patients who received antibiotics at initial presentation. This study highlights the importance of early antibiotic administration in severely ill patients with suspected infection regardless of procalcitonin levels and that the promise of procalcitonin likely lies in guiding antibiotic discontinuation rather than initiation in patients with COPD.</p><p>A confounder in the use of procalcitonin in AECOPD is that infections in AECOPD are generally less invasive than in CAP and the spectrum of bacterial pathogens differs. The degree to which procalcitonin levels correlate with the disease process is uncertain [<a href="#rid98">98</a>] because the procalcitonin levels appear to correlate with invasiveness [<a href="#rid49">49</a>] and levels may be lower in AECOPD when compared with CAP [<a href="#rid99">99</a>]. In one trial, no benefit for antibiotic use was found in patients with AECOPD and procalcitonin levels &lt;0.1 ng/mL [<a href="#rid100">100</a>]. In contrast, in a second trial, antibiotics appeared to be beneficial even when procalcitonin levels were low [<a href="#rid98">98</a>], possibly owing to anti-inflammatory effects of specific antimicrobials. Additional data in clinical settings are needed before broad use can be recommended.</p><p>The evaluation and management of infection in COPD exacerbations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/108592.html" rel="external">"Evaluation for infection in exacerbations of chronic obstructive pulmonary disease"</a> and  <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H1404102113"><span class="h4">Acute bronchitis</span><span class="headingEndMark"> — </span>We do not routinely use procalcitonin for the evaluation and management of patients with acute bronchitis. The majority of cases of acute bronchitis are caused by respiratory viruses, and antibiotics are not routinely recommended. We reserve procalcitonin testing for cases in which the diagnosis of acute bronchitis is uncertain and the need for antibiotics is unclear.</p><p>Procalcitonin has not been directly evaluated as an adjunct to clinical diagnosis in patients with acute bronchitis. In four within-study subgroup analyses of trials comparing procalcitonin-guided therapy with standard care in &gt;500 patients with acute bronchitis, there were reductions in unnecessary antibiotic use (ranging from 37 to 80 percent) without increasing adverse outcomes in the procalcitonin group [<a href="#rid27">27,28,57,101</a>]. These findings provide indirect evidence that antibiotics can be safely withheld in patients with low procalcitonin levels (eg, &lt;0.25 ng/mL) when the diagnosis of acute bronchitis is uncertain based on clinical features alone.</p><p>The evaluation and management of acute bronchitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6870.html" rel="external">"Acute bronchitis in adults"</a>.)</p><p class="headingAnchor" id="H2905781046"><span class="h2">Evaluation of dyspnea or other respiratory illnesses</span><span class="headingEndMark"> — </span>Rarely, we use procalcitonin to help narrow the differential diagnosis in patients presenting with nonspecific symptoms, such as dyspnea. Determining the etiology of dyspnea can be challenging, particularly in patients with comorbidities, such as heart failure, in whom pulmonary edema and LRTI can co-occur. When using procalcitonin diagnostically, we interpret results qualitatively  (<a class="graphic graphic_table graphicRef117054" href="/z/d/graphic/117054.html" rel="external">table 1</a>), weighting its value similarly to other clinical parameters.</p><p>In patients with dyspnea, procalcitonin has been studied as a diagnostic aid to distinguish pneumonia from heart failure. Observational data suggest adding procalcitonin to clinical judgment, and other laboratory parameters can enhance diagnostic certainty [<a href="#rid71">71,102-104</a>]. In an analysis of 453 patients presenting to the emergency department with dyspnea, median procalcitonin values were significantly higher in patients with than without clinically diagnosed pneumonia (0.38 [0.12 to 1.40] versus 0.06 [0.04 to 0.09]). A single procalcitonin level was found to be 84 percent accurate for distinguishing heart failure from pneumonia when a threshold of 0.1 ng/mL was used. Consistent results have been shown in other observational studies [<a href="#rid102">102,103</a>], though diagnostic accuracy may wane with the severity of heart failure.</p><p>There are few data evaluating clinical outcomes. In a post-hoc analysis of a cohort study evaluating 1641 patients with dyspnea, patients with confirmed acute heart failure who had procalcitonin levels &gt;0.21 ng/mL had worse outcomes when they did not receive antibiotics [<a href="#rid103">103</a>].</p><p>The accuracy of procalcitonin for differentiating other respiratory illnesses is not well established. As an example, procalcitonin does not appear to reliably differentiate aspiration pneumonitis from aspiration pneumonia [<a href="#rid105">105,106</a>]. In a prospective cohort, 65 patients admitted with pulmonary aspiration underwent bronchoalveolar lavage at time of admission; no difference in procalcitonin levels were found on day 1 or day 3 between those with positive and negative cultures [<a href="#rid105">105</a>]. Overall, further study on the diagnostic value of procalcitonin is needed.</p><p class="headingAnchor" id="H1298732737"><span class="h2">Coronavirus disease 2019 (COVID-19)</span><span class="headingEndMark"> — </span>The utility of procalcitonin in patients with COVID-19 is uncertain. Procalcitonin values are low in most patients with COVID-19 [<a href="#rid107">107-110</a>], and values appear to rise with disease severity [<a href="#rid111">111-114</a>]. This rise may be due to generic systemic inflammation and is not specific for secondary bacterial infection. </p><p>In general, we do not treat patients with COVID-19 with empiric antibiotics unless bacterial superinfection is suspected based on microbiologic testing, chest imaging (eg, dense consolidations on imaging), clinical instability, or other factors. When clinical suspicion for bacterial infection is low, a low procalcitonin value is reassuring and supports the decision to withhold or discontinue antibiotics. By contrast, an elevated procalcitonin value has poor predictive value for bacterial infection and we make the decision to start or stop antibiotics based on other factors. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Empiric treatment for bacterial pneumonia in selected patients'</a>.)</p><p class="headingAnchor" id="H416984673"><span class="h2">Limitations</span></p><p class="headingAnchor" id="H1042859270"><span class="h3">False positive and false negatives</span><span class="headingEndMark"> — </span>Procalcitonin is more specific for bacterial infections than other inflammatory markers, such as white blood cell count, erythrocyte sedimentation rate, and C-reactive protein [<a href="#rid115">115</a>]. However, false positives can still occur. Major stressors that cause systemic inflammation, such as severe trauma [<a href="#rid116">116</a>], cardiac arrest or circulatory shock [<a href="#rid117">117</a>], surgery [<a href="#rid118">118</a>], burns [<a href="#rid119">119</a>], pancreatitis [<a href="#rid120">120</a>], and intracranial hemorrhage [<a href="#rid121">121</a>] can also elevate procalcitonin levels, possibly due to gut translocation of lipopolysaccharide or other bacterial products [<a href="#rid39">39</a>]. Procalcitonin can also be elevated in the immediate postnatal period [<a href="#rid122">122</a>], after receipt of immunomodulatory agents (such as T cell antibodies, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, interleukin-2, and granulocyte transfusions) [<a href="#rid123">123-125</a>],with severe liver disease [<a href="#rid126">126</a>], and with certain neoplasms including medullary thyroid cancer [<a href="#rid127">127</a>] and other neuroendocrine tumors [<a href="#rid128">128,129</a>]. Certain autoimmune diseases, such as Kawasaki disease, can raise procalcitonin levels [<a href="#rid130">130</a>], though this does not appear to be the case with most immune disorders (eg, rheumatoid arthritis or systemic lupus erythematosus) [<a href="#rid131">131-133</a>].</p><p>Other infectious nonbacterial etiologies that increase procalcitonin include malaria [<a href="#rid134">134,135</a>] and invasive <em>Candida</em> infections [<a href="#rid136">136</a>]. However, procalcitonin levels appear to be lower in these infections when compared with bacterial infections [<a href="#rid137">137,138</a>]. Other pulmonary mold infections, including aspergillosis, mucormycosis, and coccidioidomycosis can cause low-level elevations [<a href="#rid139">139,140</a>].</p><p>Procalcitonin may not rise in contained localized infections such as tonsillitis, sinusitis, cystitis, uncomplicated skin/soft tissue infections, abscesses, or empyemas [<a href="#rid141">141,142</a>]. False negatives can also occur if procalcitonin is drawn too early in the course of infection [<a href="#rid31">31</a>]. Notably, procalcitonin production is not impaired in immunocompromised states such as neutropenia, corticosteroids, bone marrow or solid organ transplantation, and human immunodeficiency virus (HIV) [<a href="#rid143">143-147</a>].</p><p class="headingAnchor" id="H3996977984"><span class="h3">Variability among pathogens</span><span class="headingEndMark"> — </span>The degree to which procalcitonin rises varies among pathogens, with higher levels observed in patients with LRTIs caused by typical bacteria when compared with atypical bacteria or other pathogens [<a href="#rid24">24</a>].</p><p>In one multicenter study evaluating 1735 hospitalized patients with CAP, median procalcitonin levels were higher in patients with pneumonia caused by typical bacteria (2.5 ng/mL) compared with atypical bacteria (0.20 ng/mL) and viruses (0.09 ng/mL) [<a href="#rid24">24</a>]. Among atypical bacteria, <em>Legionella </em>species cause modest elevations in procalcitonin [<a href="#rid40">40,148,149</a>], while <em>Mycoplasma </em>and <em>Chlamydia</em> species may not result in detectable elevations [<a href="#rid24">24,150</a>]. The degree of rise provoked by infection with other pathogens is less well studied, although early observations suggest that invasive infection caused by typical bacteria tend to be higher than infections caused by less common pathogens including <em>Mycobacteria tuberculosis, Candida </em>species, <em>P. jirovecii</em>, and <em>Plasmodium</em> species [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H3460973510"><span class="h3">Use in special populations</span><span class="headingEndMark"> — </span>It is unclear how to interpret procalcitonin levels in patients with renal impairment; in immunocompromised, pregnant, or surgical patients; or in other patients under severe physiologic stress. Procalcitonin use is not precluded in these populations, but clinicians should be aware of the assay's limitations when interpreting results.</p><p class="headingAnchor" id="H716085739"><span class="h4">Chronic kidney disease</span><span class="headingEndMark"> — </span>Persons with chronic kidney disease (CKD) have higher baseline levels of procalcitonin, believed to be due to higher levels of circulating inflammatory cytokines [<a href="#rid151">151,152</a>]. In one study, the average procalcitonin level in healthy persons with CKD prior to starting renal replacement was 1.82 ± 0.39 ng/mL [<a href="#rid153">153</a>]. Levels drop with renal replacement therapy. Average levels in patients with CKD receiving hemodialysis range from 0.26 ng/ mL to 1.0 ng/mL prior to dialysis sessions [<a href="#rid151">151</a>]. After dialysis, levels decline by 20 to 80 percent, varying with the mode of dialysis used. Despite higher baseline levels, procalcitonin does rise in the setting of infection in patients with CKD [<a href="#rid154">154</a>]. However, the rate of rise may be slower than in healthy patients [<a href="#rid55">55,151</a>]. Elimination is marginally prolonged in patients with CKD, with a mean half-life of 28.9 hours in healthy patients compared with 33 hours in patients with creatine clearance &lt;30 mL/minute.</p><p>Because of these dynamics, some experts suggest that higher procalcitonin thresholds be used for patients with renal dysfunction [<a href="#rid151">151</a>]. Others suggest that single procalcitonin levels are unreliable in patients with CKD and propose that trends in procalcitonin levels have greater predictive value [<a href="#rid153">153</a>]. Additional studies are needed to determine how to best use procalcitonin in this population and whether use is associated with reduction in unnecessary antibiotic prescription.</p><p class="headingAnchor" id="H3298855350"><span class="h4">Immunocompromise</span><span class="headingEndMark"> — </span>Immunocompromised patients, apart from patients receiving corticosteroids, have generally been excluded from trials evaluating procalcitonin efficacy. However, observational studies suggest that procalcitonin levels correlate with the presence of bacterial infection and the severity of infection in this population [<a href="#rid144">144,155-158</a>]. Baseline procalcitonin levels tend to be higher in this population (possibly due to other concurrent causes of systemic inflammation), and optimal thresholds for guiding antibiotic therapy have not yet been determined [<a href="#rid159">159</a>]. Because morbidity from bacterial infections can be high in this population, and because immunocompromised patients may require longer durations of antibiotics in general, we typically do not use procalcitonin to guide antibiotic discontinuation in immunocompromised individuals.</p><p class="headingAnchor" id="H1091048477"><span class="h4">Surgery and trauma</span><span class="headingEndMark"> — </span>Severe physiologic stressors such as surgery, trauma, or burns can lead to procalcitonin elevations [<a href="#rid49">49,160</a>]. While patients with these conditions were not excluded from trials evaluating procalcitonin, they represent a minority of cases in large trials [<a href="#rid28">28,29</a>]. Aggregated data from small studies suggest that procalcitonin has moderate diagnostic accuracy for sepsis in surgical and trauma patients [<a href="#rid161">161</a>] but, as with other special populations, further study is needed to inform practice [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H1183786169"><span class="h1">PRACTICAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>Procalcitonin assays are not available at all institutions. Because the usefulness of the assay is dependent on rapid turnaround time, testing should only be obtained at centers where results can be obtained in a timely manner. Several different commercial procalcitonin assays are available in the United States. Most demonstrate good concordance at clinically relevant thresholds [<a href="#rid162">162</a>]. One large randomized controlled trial allowed the use of different analyzers according to site availability, with no difference in recommended thresholds among assays [<a href="#rid74">74</a>].</p><p>Overall, knowledge of procalcitonin is evolving and additional studies performed in clinical settings are needed to refine its use. As an example, in the ProACT randomized trial evaluating 1656 patients presenting to the emergency departments with an acute lower respiratory tract infection of any kind (ie, asthma exacerbation, acute chronic obstructive pulmonary disease exacerbation, acute bronchitis, and community-acquired pneumonia), procalcitonin-guided antibiotic initiation or discontinuation did not result in decreased antibiotic use when compared with usual care [<a href="#rid60">60</a>]. Importantly, the hospitals included in this trial all had high adherence to quality measures for the treatment of pneumonia. Similarly, in a pragmatic randomized trial evaluating 285 patients with presumed CAP in the emergency departments of 12 French hospitals, antibiotic duration was similar when comparing procalcitonin-guided antibiotic use versus serial guideline-based clinical assessment (10 versus 9 days) [<a href="#rid163">163</a>]. Clinical success and adverse event rates did not differ between groups. The lack of benefit for procalcitonin use in these trials may reflect increased provider knowledge of appropriate antibiotic prescribing practices. </p><p>As with these trials, many existing studies on procalcitonin are limited by a necessary lack of blinding, lack of a reliable reference standard for the diagnosis of bacterial lower respiratory tract infections, variable baseline antibiotic prescription rates, and incomplete algorithm adherence. It remains to be seen if procalcitonin algorithms will continue to be effective as rigorous antimicrobial stewardship programs are implemented and knowledge of appropriate antibiotic use grows. Preliminary data suggest that procalcitonin use can add value to antimicrobial stewardship programs [<a href="#rid164">164</a>].</p><p>Use of procalcitonin algorithms should never override clinical judgment. In most trials, algorithms were often overruled by clinical judgment, underscoring the fact that the assay should be used as an adjunct to clinical judgment and not a replacement.</p><p class="headingAnchor" id="H2737266587"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104226.html" rel="external">"Society guideline links: Community-acquired pneumonia in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109779.html" rel="external">"Society guideline links: Hospital-acquired pneumonia and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115162.html" rel="external">"Society guideline links: Antimicrobial stewardship"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H2786522145"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> − Procalcitonin is a serum biomarker that helps distinguish bacterial infection from other causes of infection or inflammation. In patients with lower respiratory tract infections (LRTIs), procalcitonin can serve as a helpful adjunct to clinical judgment for guiding antibiotic therapy and resolving diagnostic uncertainty. (See <a class="local">'Introduction'</a> above and <a class="local">'Rationale for use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guiding early antibiotic discontinuation in patients hospitalized with CAP</strong> − We primarily use procalcitonin to guide early antibiotic discontinuation in hospitalized patients with community-acquired pneumonia (CAP)  (<a class="graphic graphic_algorithm graphicRef117052" href="/z/d/graphic/117052.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinically stable patients</strong> − We generally obtain a level at the time of diagnosis and repeat the level every two days in patients who are clinically stable. We determine the need for continued antibiotic therapy based on clinical improvement and serial procalcitonin levels. (See <a class="local">'Clinically stable patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Critically ill patients</strong> − For patients with CAP who are critically ill or septic at the time of hospitalization, we generally obtain a procalcitonin level daily and consider discontinuing antibiotics when levels are &lt;0.5 ng/mL (or decreased by ≥80 percent from peak when then initial level was &gt;5 ng/mL) and the patient has stabilized. (See <a class="local">'Critically ill patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncertain value for guiding antibiotic initiation</strong> − Using procalcitonin levels to help determine whether to start antibiotics in a patient with CAP is controversial. For most patients with known or suspected CAP, we treat with empiric antibiotics regardless of the initial procalcitonin level. For selected patients who are clinically stable and lack major comorbidities, we consider withholding antibiotics when the clinical presentation and/or laboratory results strongly suggest a viral infection and the procalcitonin level is &lt;0.25. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use in outpatients with CAP</strong> – The approach to using procalcitonin levels to guide antibiotic-decision making for outpatients with CAP varies among experts. When the test is available and turnaround time is quick, some experts use procalcitonin in conjunction with a positive test for a viral pathogen (eg, influenza) to withhold antibiotics or stop them early (provided the patient has close follow-up). Other experts prefer to treat empirically with antibiotics because bacterial CAP is hard to exclude definitively, the morbidity association with CAP is high, and outpatient treatment courses for CAP are short (eg, five days). (See <a class="local">'Community-acquired pneumonia in outpatients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other respiratory tract infections</strong> − For patients with other lower respiratory tract infections such as ventilator-associated pneumonia, acute bronchitis, and chronic obstructive pulmonary disease exacerbations, we do not routinely use procalcitonin in evaluation and management. We suggest that procalcitonin testing be reserved for selected cases. (See <a class="local">'Other lower respiratory tract infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Helping narrow a differential diagnosis</strong> − Occasionally, we use procalcitonin to help narrow the differential diagnosis in patients presenting with nonspecific symptoms such as dyspnea (eg, to help distinguish pneumonia from heart failure). When using procalcitonin diagnostically, we interpret results qualitatively  (<a class="graphic graphic_table graphicRef117054" href="/z/d/graphic/117054.html" rel="external">table 1</a>) and in conjunction with other clinical findings. (See <a class="local">'Evaluation of dyspnea or other respiratory illnesses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Key caveats – </strong>The study of procalcitonin is evolving and use of procalcitonin algorithms should never override clinical judgment. In most trials, algorithms were commonly overruled by clinical judgment, underscoring the fact that the assay should be used as an adjunct to clinical judgment and not a replacement. (See <a class="local">'Practical considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>False positives and false negatives</strong> − When interpreting procalcitonin levels, clinicians should be aware of factors that cause procalcitonin levels to rise apart from bacterial LRTI and how the magnitude of procalcitonin elevation varies among pathogens  (<a class="graphic graphic_table graphicRef117053" href="/z/d/graphic/117053.html" rel="external">table 2</a>). (See <a class="local">'False positive and false negatives'</a> above and <a class="local">'Variability among pathogens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use in special populations</strong> − Procalcitonin has not been well studied in certain populations, such as immunocompromised patients, surgical patients, and patients with chronic kidney disease. While procalcitonin use is not precluded in these populations, clinicians should be aware of the assay's limitations when interpreting results. (See <a class="local">'Use in special populations'</a> above.)</p><p></p><p class="headingAnchor" id="H4074677597"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Harris AM, Hicks LA, Qaseem A, High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2016; 164:425.</a></li><li class="breakAll">Choosing Wisely Canada http://www.choosingwiselycanada.org/recommendations/emergency-medicine/ (Accessed on March 16, 2017).</li><li class="breakAll">National Quality Forum (NQF). Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis. Available at: http://www.qualityforum.org/MeasureDetails.aspx?actid=0&amp;SubmissionId=1216#p=5&amp;s=n&amp;so=a (Accessed on October 04, 2017).</li><li class="breakAll">National Institute for Health and Care Excellence. Cough (acute): antimicrobial prescribing https://www.nice.org.uk/guidance/ng120/resources/cough-acute-antimicrobial-prescribing-pdf-66141652166341 (Accessed on February 26, 2021).</li><li><a class="nounderline abstract_t">Huttner A, Harbarth S, Carlet J, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control 2013; 2:31.</a></li><li class="breakAll">McDonagh M, Peterson K, Winthrop K, et al. Improving Antibiotic Prescribing for Uncomplicated Acute Respiratory Tract Infections, Agency for Healthcare Research and Quality, Rockville&lt; MD 2016.</li><li><a class="nounderline abstract_t">Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009; 302:758.</a></li><li><a class="nounderline abstract_t">Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. JAMA 2016; 315:1864.</a></li><li><a class="nounderline abstract_t">Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother 2014; 69:234.</a></li><li><a class="nounderline abstract_t">Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep 2014; 63:194.</a></li><li><a class="nounderline abstract_t">McKay R, Mah A, Law MR, et al. Systematic Review of Factors Associated with Antibiotic Prescribing for Respiratory Tract Infections. Antimicrob Agents Chemother 2016; 60:4106.</a></li><li><a class="nounderline abstract_t">Kraus EM, Pelzl S, Szecsenyi J, Laux G. Antibiotic prescribing for acute lower respiratory tract infections (LRTI) - guideline adherence in the German primary care setting: An analysis of routine data. PLoS One 2017; 12:e0174584.</a></li><li><a class="nounderline abstract_t">Silverman M, Povitz M, Sontrop JM, et al. Antibiotic Prescribing for Nonbacterial Acute Upper Respiratory Infections in Elderly Persons. Ann Intern Med 2017; 166:765.</a></li><li><a class="nounderline abstract_t">McCullough AR, Pollack AJ, Plejdrup Hansen M, et al. Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations. Med J Aust 2017; 207:65.</a></li><li><a class="nounderline abstract_t">Ebell MH, Radke T. Antibiotic use for viral acute respiratory tract infections remains common. Am J Manag Care 2015; 21:e567.</a></li><li><a class="nounderline abstract_t">Hecker MT, Aron DC, Patel NP, et al. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003; 163:972.</a></li><li><a class="nounderline abstract_t">Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis 2016; 62:817.</a></li><li><a class="nounderline abstract_t">Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.</a></li><li><a class="nounderline abstract_t">Lieberman D, Shimoni A, Shemer-Avni Y, et al. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010; 138:811.</a></li><li><a class="nounderline abstract_t">Clark TW, Medina MJ, Batham S, et al. Adults hospitalised with acute respiratory illness rarely have detectable bacteria in the absence of COPD or pneumonia; viral infection predominates in a large prospective UK sample. J Infect 2014; 69:507.</a></li><li><a class="nounderline abstract_t">Creer DD, Dilworth JP, Gillespie SH, et al. Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax 2006; 61:75.</a></li><li><a class="nounderline abstract_t">Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355.</a></li><li><a class="nounderline abstract_t">Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173:1114.</a></li><li><a class="nounderline abstract_t">Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis 2017; 65:183.</a></li><li><a class="nounderline abstract_t">Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; :CD007498.</a></li><li><a class="nounderline abstract_t">Tonkin-Crine SK, Tan PS, van Hecke O, et al. Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews. Cochrane Database Syst Rev 2017; 9:CD012252.</a></li><li><a class="nounderline abstract_t">Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600.</a></li><li><a class="nounderline abstract_t">Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059.</a></li><li><a class="nounderline abstract_t">Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10:CD007498.</a></li><li><a class="nounderline abstract_t">Becker KL, Nylén ES, White JC, et al. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512.</a></li><li><a class="nounderline abstract_t">Christ-Crain M, Müller B. Procalcitonin in bacterial infections--hype, hope, more or less? Swiss Med Wkly 2005; 135:451.</a></li><li><a class="nounderline abstract_t">Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res 2000; 49 Suppl 1:S57.</a></li><li><a class="nounderline abstract_t">Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48:2325.</a></li><li><a class="nounderline abstract_t">Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605.</a></li><li><a class="nounderline abstract_t">Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515.</a></li><li><a class="nounderline abstract_t">Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164:396.</a></li><li><a class="nounderline abstract_t">Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011; 52 Suppl 4:S346.</a></li><li><a class="nounderline abstract_t">Müller B, Becker KL, Schächinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28:977.</a></li><li><a class="nounderline abstract_t">Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36:941.</a></li><li><a class="nounderline abstract_t">Stockmann C, Ampofo K, Killpack J, et al. Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia. J Pediatric Infect Dis Soc 2018; 7:46.</a></li><li><a class="nounderline abstract_t">Thomas-Rüddel DO, Poidinger B, Kott M, et al. Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia. Crit Care 2018; 22:128.</a></li><li><a class="nounderline abstract_t">Schleicher GK, Herbert V, Brink A, et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 2005; 25:688.</a></li><li><a class="nounderline abstract_t">Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006; 10:510.</a></li><li><a class="nounderline abstract_t">Raineri SM, Cortegiani A, Vitale F, et al. Procalcitonin for the diagnosis of invasive candidiasis: what is the evidence? J Intensive Care 2017; 5:58.</a></li><li><a class="nounderline abstract_t">Cortegiani A, Russotto V, Montalto F, et al. Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol 2014; 14:9.</a></li><li><a class="nounderline abstract_t">Dou YH, Du JK, Liu HL, Shong XD. The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis. Diagn Microbiol Infect Dis 2013; 76:464.</a></li><li><a class="nounderline abstract_t">Bruneel F, Tubach F, Mira JP, et al. Imported falciparum malaria in adults: host- and parasite-related factors associated with severity. The French prospective multicenter PALUREA cohort study. Intensive Care Med 2016; 42:1588.</a></li><li><a class="nounderline abstract_t">Righi E, Merelli M, Arzese A, et al. Determination of PCT on admission is a useful tool for the assessment of disease severity in travelers with imported Plasmodium falciparum malaria. Acta Parasitol 2016; 61:412.</a></li><li><a class="nounderline abstract_t">Gilbert DN. Role of Procalcitonin in the Management of Infected Patients in the Intensive Care Unit. Infect Dis Clin North Am 2017; 31:435.</a></li><li><a class="nounderline abstract_t">Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014; 34:263.</a></li><li><a class="nounderline abstract_t">Schuetz P, Maurer P, Punjabi V, et al. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013; 17:R115.</a></li><li><a class="nounderline abstract_t">Vijayan AL, Vanimaya, Ravindran S, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care 2017; 5:51.</a></li><li><a class="nounderline abstract_t">Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84.</a></li><li><a class="nounderline abstract_t">Long W, Deng X, Zhang Y, et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011; 16:819.</a></li><li><a class="nounderline abstract_t">Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463.</a></li><li><a class="nounderline abstract_t">Walsh TL, DiSilvio BE, Hammer C, et al. Impact of Procalcitonin Guidance with an Educational Program on Management of Adults Hospitalized with Pneumonia. Am J Med 2018; 131:201.e1.</a></li><li><a class="nounderline abstract_t">Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018; 18:95.</a></li><li><a class="nounderline abstract_t">Wilson KC, Schoenberg NC, Cohn DL, et al. Community-acquired Pneumonia Guideline Recommendations-Impact of a Consensus-based Process versus Systematic Reviews. Clin Infect Dis 2021; 73:e1467.</a></li><li><a class="nounderline abstract_t">Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med 2019; 57:1308.</a></li><li><a class="nounderline abstract_t">Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. N Engl J Med 2018; 379:236.</a></li><li><a class="nounderline abstract_t">Le Bel J, Hausfater P, Chenevier-Gobeaux C, et al. Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan. Crit Care 2015; 19:366.</a></li><li><a class="nounderline abstract_t">Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7:10.</a></li><li><a class="nounderline abstract_t">Pfister R, Kochanek M, Leygeber T, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care 2014; 18:R44.</a></li><li><a class="nounderline abstract_t">Fontela PS, Papenburg J. Procalcitonin and antibiotic use: imperfect, yet effective. Lancet Infect Dis 2018; 18:11.</a></li><li><a class="nounderline abstract_t">Branche AR, Walsh EE, Vargas R, et al. Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial. J Infect Dis 2015; 212:1692.</a></li><li><a class="nounderline abstract_t">Kutz A, Briel M, Christ-Crain M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Crit Care 2015; 19:74.</a></li><li><a class="nounderline abstract_t">Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32:469.</a></li><li><a class="nounderline abstract_t">Bloos F, Marshall JC, Dellinger RP, et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 2011; 15:R88.</a></li><li><a class="nounderline abstract_t">McCluskey SM, Schuetz P, Abers MS, et al. Serial Procalcitonin as a Predictor of Bacteremia and Need for Intensive Care Unit Care in Adults With Pneumonia, Including Those With Highest Severity: A Prospective Cohort Study. Open Forum Infect Dis 2017; 4:ofw238.</a></li><li><a class="nounderline abstract_t">Schuetz P, Birkhahn R, Sherwin R, et al. Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study. Crit Care Med 2017; 45:781.</a></li><li><a class="nounderline abstract_t">Alba GA, Truong QA, Gaggin HK, et al. Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea. Am J Med 2016; 129:96.</a></li><li><a class="nounderline abstract_t">Tejerina E, Esteban A, Fernández-Segoviano P, et al. Accuracy of clinical definitions of ventilator-associated pneumonia: comparison with autopsy findings. J Crit Care 2010; 25:62.</a></li><li><a class="nounderline abstract_t">Bishop BM, Bon JJ, Trienski TL, et al. Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Ann Pharmacother 2014; 48:577.</a></li><li><a class="nounderline abstract_t">de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16:819.</a></li><li><a class="nounderline abstract_t">Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498.</a></li><li><a class="nounderline abstract_t">Hochreiter M, Köhler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009; 13:R83.</a></li><li><a class="nounderline abstract_t">Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009; 394:221.</a></li><li><a class="nounderline abstract_t">Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 2014; 190:1102.</a></li><li><a class="nounderline abstract_t">Deliberato RO, Marra AR, Sanches PR, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis 2013; 76:266.</a></li><li><a class="nounderline abstract_t">Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial. Am J Respir Crit Care Med 2021; 203:202.</a></li><li><a class="nounderline abstract_t">Barlam TF, Cosgrove SE, Abbo LM, et al. Executive Summary: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62:1197.</a></li><li><a class="nounderline abstract_t">Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49:e1063.</a></li><li><a class="nounderline abstract_t">Lhopitallier L, Kronenberg A, Meuwly JY, et al. Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial. BMJ 2021; 374:n2132.</a></li><li><a class="nounderline abstract_t">Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008; 34:1434.</a></li><li><a class="nounderline abstract_t">Dallas J, Brown SM, Hock K, et al. Diagnostic utility of plasma procalcitonin for nosocomial pneumonia in the intensive care unit setting. Respir Care 2011; 56:412.</a></li><li><a class="nounderline abstract_t">Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008; 31:356.</a></li><li><a class="nounderline abstract_t">Luyt CE, Combes A, Trouillet JL, Chastre J. Value of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumonia. Semin Respir Crit Care Med 2011; 32:181.</a></li><li><a class="nounderline abstract_t">Svoboda P, Kantorová I, Scheer P, et al. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery? Hepatogastroenterology 2007; 54:359.</a></li><li><a class="nounderline abstract_t">Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</a></li><li><a class="nounderline abstract_t">Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev 2017; 26.</a></li><li><a class="nounderline abstract_t">Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:9.</a></li><li><a class="nounderline abstract_t">Kristoffersen KB, Søgaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. Clin Microbiol Infect 2009; 15:481.</a></li><li><a class="nounderline abstract_t">Corti C, Fally M, Fabricius-Bjerre A, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis 2016; 11:1381.</a></li><li><a class="nounderline abstract_t">Verduri A, Luppi F, D'Amico R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One 2015; 10:e0118241.</a></li><li><a class="nounderline abstract_t">Bremmer DN, DiSilvio BE, Hammer C, et al. Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations. J Gen Intern Med 2018; 33:692.</a></li><li><a class="nounderline abstract_t">Daubin C, Valette X, Thiollière F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med 2018; 44:428.</a></li><li><a class="nounderline abstract_t">Daniels JM, Schoorl M, Snijders D, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010; 138:1108.</a></li><li><a class="nounderline abstract_t">Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011; 139:1410.</a></li><li><a class="nounderline abstract_t">Wang JX, Zhang SM, Li XH, et al. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. Int J Infect Dis 2016; 48:40.</a></li><li><a class="nounderline abstract_t">Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008; 168:2000.</a></li><li><a class="nounderline abstract_t">Wang W, Zhang X, Ge N, et al. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. Crit Care 2014; 18:R4.</a></li><li><a class="nounderline abstract_t">Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail 2012; 14:278.</a></li><li><a class="nounderline abstract_t">Yoon YK, Kim MJ, Yang KS, Ham SY. The role of serum procalcitonin in the differential diagnosis of pneumonia from pulmonary edema among the patients with pulmonary infiltrates on chest radiography. Medicine (Baltimore) 2018; 97:e13348.</a></li><li><a class="nounderline abstract_t">El-Solh AA, Vora H, Knight PR 3rd, Porhomayon J. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. Crit Care Med 2011; 39:1251.</a></li><li><a class="nounderline abstract_t">Legriel S, Grigoresco B, Martel P, et al. Diagnostic Accuracy of Procalcitonin for Early Aspiration Pneumonia in Critically Ill Patients with Coma: A Prospective Study. Neurocrit Care 2019; 30:440.</a></li><li><a class="nounderline abstract_t">Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507.</a></li><li><a class="nounderline abstract_t">Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497.</a></li><li><a class="nounderline abstract_t">Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061.</a></li><li><a class="nounderline abstract_t">Chen X, Yang Y, Huang M, et al. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: A retrospective study from a single center. J Med Virol 2020; 92:1572.</a></li><li><a class="nounderline abstract_t">Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta 2020; 505:190.</a></li><li><a class="nounderline abstract_t">Atallah NJ, Warren HM, Roberts MB, et al. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study. PLoS One 2022; 17:e0262342.</a></li><li><a class="nounderline abstract_t">Metlay JP, Waterer GW. Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. Ann Intern Med 2020; 173:304.</a></li><li><a class="nounderline abstract_t">Fabre V, Karaba S, Amoah J, et al. The role of procalcitonin results in antibiotic decision-making in coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol 2022; 43:570.</a></li><li><a class="nounderline abstract_t">BalcI C, Sungurtekin H, Gürses E, et al. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003; 7:85.</a></li><li><a class="nounderline abstract_t">Mimoz O, Benoist JF, Edouard AR, et al. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1998; 24:185.</a></li><li><a class="nounderline abstract_t">Annborn M, Dankiewicz J, Erlinge D, et al. Procalcitonin after cardiac arrest - an indicator of severity of illness, ischemia-reperfusion injury and outcome. Resuscitation 2013; 84:782.</a></li><li><a class="nounderline abstract_t">Meisner M, Tschaikowsky K, Hutzler A, et al. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998; 24:680.</a></li><li><a class="nounderline abstract_t">Carsin H, Assicot M, Feger F, et al. Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF alpha and endotoxin levels early after thermal injury. Burns 1997; 23:218.</a></li><li><a class="nounderline abstract_t">Kylänpää-Bäck ML, Takala A, Kemppainen EA, et al. Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis. Crit Care Med 2001; 29:63.</a></li><li><a class="nounderline abstract_t">Muroi C, Lemb JB, Hugelshofer M, et al. Early systemic procalcitonin levels in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 2014; 21:73.</a></li><li><a class="nounderline abstract_t">Chiesa C, Pellegrini G, Panero A, et al. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003; 49:60.</a></li><li><a class="nounderline abstract_t">Dornbusch HJ, Strenger V, Sovinz P, et al. Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. Support Care Cancer 2008; 16:1035.</a></li><li><a class="nounderline abstract_t">Sabat R, Höflich C, Döcke WD, et al. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med 2001; 27:987.</a></li><li><a class="nounderline abstract_t">Dornbusch HJ, Strenger V, Kerbl R, et al. Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and Gram-negative sepsis. Bone Marrow Transplant 2003; 32:941.</a></li><li><a class="nounderline abstract_t">Dong R, Wan B, Lin S, et al. Procalcitonin and Liver Disease: A Literature Review. J Clin Transl Hepatol 2019; 7:51.</a></li><li><a class="nounderline abstract_t">Karagiannis AK, Girio-Fragkoulakis C, Nakouti T. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. Anticancer Res 2016; 36:3803.</a></li><li><a class="nounderline abstract_t">Patout M, Salaün M, Brunel V, et al. Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem 2014; 47:263.</a></li><li><a class="nounderline abstract_t">Chen L, Zhang Y, Lin Y, et al. The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. Clin Biochem 2017; 50:982.</a></li><li><a class="nounderline abstract_t">Yoshikawa H, Nomura Y, Masuda K, et al. Serum procalcitonin value is useful for predicting severity of Kawasaki disease. Pediatr Infect Dis J 2012; 31:523.</a></li><li><a class="nounderline abstract_t">Quintana G, Medina YF, Rojas C, et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol 2008; 14:138.</a></li><li><a class="nounderline abstract_t">Brunkhorst R, Eberhardt OK, Haubitz M, Brunkhorst FM. Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection. Intensive Care Med 2000; 26 Suppl 2:S199.</a></li><li><a class="nounderline abstract_t">Sato H, Tanabe N, Murasawa A, et al. Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol 2012; 39:1517.</a></li><li><a class="nounderline abstract_t">Uzzan B, Izri A, Durand R, et al. Serum procalcitonin in uncomplicated falciparum malaria: a preliminary study. Travel Med Infect Dis 2006; 4:77.</a></li><li><a class="nounderline abstract_t">Chiwakata CB, Manegold C, Bönicke L, et al. Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria. J Infect Dis 2001; 183:1161.</a></li><li><a class="nounderline abstract_t">Charles PE, Castro C, Ruiz-Santana S, et al. Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? Intensive Care Med 2009; 35:2146.</a></li><li><a class="nounderline abstract_t">Leli C, Ferranti M, Moretti A, et al. Procalcitonin levels in gram-positive, gram-negative, and fungal bloodstream infections. Dis Markers 2015; 2015:701480.</a></li><li><a class="nounderline abstract_t">Charles PE, Dalle F, Aho S, et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 2006; 32:1577.</a></li><li><a class="nounderline abstract_t">Roques M, Chretien ML, Favennec C, et al. Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis. Mycoses 2016; 59:383.</a></li><li><a class="nounderline abstract_t">Sakata KK, Grys TE, Chang YH, et al. Serum procalcitonin levels in patients with primary pulmonary coccidioidomycosis. Ann Am Thorac Soc 2014; 11:1239.</a></li><li><a class="nounderline abstract_t">Christensen AM, Thomsen MK, Ovesen T, Klug TE. Are procalcitonin or other infection markers useful in the detection of group A streptococcal acute tonsillitis? Scand J Infect Dis 2014; 46:376.</a></li><li><a class="nounderline abstract_t">Pallin DJ, Bry L, Dwyer RC, et al. Toward an Objective Diagnostic Test for Bacterial Cellulitis. PLoS One 2016; 11:e0162947.</a></li><li><a class="nounderline abstract_t">von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004; 23:539.</a></li><li><a class="nounderline abstract_t">Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, et al. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001; 32:1718.</a></li><li><a class="nounderline abstract_t">Koya J, Nannya Y, Ichikawa M, Kurokawa M. The clinical role of procalcitonin in hematopoietic SCT. Bone Marrow Transplant 2012; 47:1326.</a></li><li><a class="nounderline abstract_t">Perren A, Cerutti B, Lepori M, et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008; 36:163.</a></li><li><a class="nounderline abstract_t">Tokman S, Barnett CF, Jarlsberg LG, et al. Procalcitonin predicts mortality in HIV-infected Ugandan adults with lower respiratory tract infections. Respirology 2014; 19:382.</a></li><li><a class="nounderline abstract_t">Haeuptle J, Zaborsky R, Fiumefreddo R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28:55.</a></li><li><a class="nounderline abstract_t">Bellmann-Weiler R, Ausserwinkler M, Kurz K, et al. Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia. J Clin Microbiol 2010; 48:1915.</a></li><li><a class="nounderline abstract_t">Schützle H, Forster J, Superti-Furga A, Berner R. Is serum procalcitonin a reliable diagnostic marker in children with acute respiratory tract infections? A retrospective analysis. Eur J Pediatr 2009; 168:1117.</a></li><li><a class="nounderline abstract_t">Grace E, Turner RM. Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy. Clin Infect Dis 2014; 59:1761.</a></li><li><a class="nounderline abstract_t">Kubo S, Iwasaki M, Horie M, et al. Biological variation of procalcitonin levels in hemodialysis patients. Clin Exp Nephrol 2019; 23:402.</a></li><li><a class="nounderline abstract_t">Meisner M, Schmidt J, Hüttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 2000; 26 Suppl 2:S212.</a></li><li><a class="nounderline abstract_t">Takahashi G, Shibata S, Fukui Y, et al. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury. Diagn Microbiol Infect Dis 2016; 86:205.</a></li><li><a class="nounderline abstract_t">Bele N, Darmon M, Coquet I, et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis 2011; 11:224.</a></li><li><a class="nounderline abstract_t">Schüttrumpf S, Binder L, Hagemann T, et al. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol 2003; 82:98.</a></li><li><a class="nounderline abstract_t">Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis 2006; 43:1468.</a></li><li><a class="nounderline abstract_t">Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? Cancer 2012; 118:5823.</a></li><li><a class="nounderline abstract_t">El Haddad H, Chaftari AM, Hachem R, et al. Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. Clin Infect Dis 2018; 67:971.</a></li><li><a class="nounderline abstract_t">Clec'h C, Fosse JP, Karoubi P, et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006; 34:102.</a></li><li><a class="nounderline abstract_t">Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996.</a></li><li><a class="nounderline abstract_t">Dipalo M, Guido L, Micca G, et al. Multicenter comparison of automated procalcitonin immunoassays. Pract Lab Med 2015; 2:22.</a></li><li><a class="nounderline abstract_t">Montassier E, Javaudin F, Moustafa F, et al. Guideline-Based Clinical Assessment Versus Procalcitonin-Guided Antibiotic Use in Pneumonia: A Pragmatic Randomized Trial. Ann Emerg Med 2019; 74:580.</a></li><li><a class="nounderline abstract_t">Broyles MR. Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence. Open Forum Infect Dis 2017; 4:ofx213.</a></li></ol></div><div id="topicVersionRevision">Topic 114753 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26785402" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26785402" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26785402" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26785402" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24237856" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24237856" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690308" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27139059" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23887867" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24598596" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vital signs: improving antibiotic use among hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27139474" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systematic Review of Factors Associated with Antibiotic Prescribing for Respiratory Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28350820" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antibiotic prescribing for acute lower respiratory tract infections (LRTI) - guideline adherence in the German primary care setting: An analysis of routine data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492914" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibiotic Prescribing for Nonbacterial Acute Upper Respiratory Infections in Elderly Persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28701117" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26619058" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antibiotic use for viral acute respiratory tract infections remains common.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12719208" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26747825" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20363845" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Respiratory viruses in adults with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25108123" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adults hospitalised with acute respiratory illness rarely have detectable bacteria in the absence of COPD or pneumonia; viral infection predominates in a large prospective UK sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227331" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038881" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Infection in the pathogenesis and course of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484677" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28407054" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972110" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28881002" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14987884" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19738090" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025194" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070906" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16208582" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Procalcitonin in bacterial infections--hype, hope, more or less?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10984072" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Physiology and genetics of procalcitonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421436" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of plasma procalcitonin levels as an adjunct to clinical microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7989463" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Procalcitonin increase after endotoxin injection in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8094770" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High serum procalcitonin concentrations in patients with sepsis and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11500339" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460294" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Procalcitonin as a biomarker in respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809269" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18431284" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28158460" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29753321" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15802344" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704032" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28975031" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Procalcitonin for the diagnosis of invasive candidiasis: what is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24559080" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23711529" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169586" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Imported falciparum malaria in adults: host- and parasite-related factors associated with severity. The French prospective multicenter PALUREA cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27078668" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Determination of PCT on admission is a useful tool for the assessment of disease severity in travelers with imported Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28779830" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Role of Procalcitonin in the Management of Infected Patients in the Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24982830" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Update on procalcitonin measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23787145" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28794881" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16603606" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21507143" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20097417" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28947168" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impact of Procalcitonin Guidance with an Educational Program on Management of Adults Hospitalized with Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29037960" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32964218" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Community-acquired Pneumonia Guideline Recommendations-Impact of a Consensus-based Process versus Systematic Reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30721141" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781385" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26472401" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17335562" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24612487" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29037959" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Procalcitonin and antibiotic use: imperfect, yet effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25910632" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887979" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prognostic value of procalcitonin in respiratory tract infections across clinical settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477418" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385367" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480236" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Serial Procalcitonin as a Predictor of Bacteremia and Need for Intensive Care Unit Care in Adults With Pneumonia, Including Those With Highest Severity: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28257335" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169892" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19592209" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Accuracy of clinical definitions of ventilator-associated pneumonia: comparison with autopsy findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24519479" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26947523" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18096708" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19493352" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19034493" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25295709" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23711530" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32757963" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118828" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Executive Summary: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34605781" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34548312" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18421435" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255510" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Diagnostic utility of plasma procalcitonin for nosocomial pneumonia in the intensive care unit setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959634" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21506054" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Value of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17523274" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418577" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28890434" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143877" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218551" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416298" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27382274" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25760346" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29404940" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29663044" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20576731" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030489" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27155210" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18852401" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24393388" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302662" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30461655" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The role of serum procalcitonin in the differential diagnosis of pneumonia from pulmonary edema among the patients with pulmonary infiltrates on chest radiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21283001" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30267280" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diagnostic Accuracy of Procalcitonin for Early Aspiration Pneumonia in Critically Ill Patients with Coma: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32007143" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31986264" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32031570" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32237148" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: A retrospective study from a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145275" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35025929" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32379883" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33866995" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The role of procalcitonin results in antibiotic decision-making in coronavirus disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12617745" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9539079" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23313427" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Procalcitonin after cardiac arrest - an indicator of severity of illness, ischemia-reperfusion injury and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9722037" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Postoperative plasma concentrations of procalcitonin after different types of surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9232281" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF alpha and endotoxin levels early after thermal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176162" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23839707" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Early systemic procalcitonin levels in patients with aneurysmal subarachnoid hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12507961" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18196287" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11497157" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561996" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and Gram-negative sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944820" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Procalcitonin and Liver Disease: A Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27466480" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25218831" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28668469" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22189525" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Serum procalcitonin value is useful for predicting severity of Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525431" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : The use of procalcitonin determinations in evaluation of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18470720" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753652" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887728" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Serum procalcitonin in uncomplicated falciparum malaria: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11237849" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19760210" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25852221" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Procalcitonin levels in gram-positive, gram-negative, and fungal bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896850" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26931315" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25168059" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Serum procalcitonin levels in patients with primary pulmonary coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24606046" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Are procalcitonin or other infection markers useful in the detection of group A streptococcal acute tonsillitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27656884" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Toward an Objective Diagnostic Test for Bacterial Cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15221617" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11360214" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343672" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : The clinical role of procalcitonin in hematopoietic SCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18330505" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24460728" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Procalcitonin predicts mortality in HIV-infected Ugandan adults with lower respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18677519" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Prognostic value of procalcitonin in Legionella pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20220163" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19107517" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Is serum procalcitonin a reliable diagnostic marker in children with acute respiratory tract infections? A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25228701" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30196520" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Biological variation of procalcitonin levels in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18470722" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : The natural elimination rate of procalcitonin in patients with normal and impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27489118" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21864380" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601488" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17083024" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Rifapentine for the treatment of pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22605389" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29668936" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374163" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16715031" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28932801" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Multicenter comparison of automated procalcitonin immunoassays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982631" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Guideline-Based Clinical Assessment Versus Procalcitonin-Guided Antibiotic Use in Pneumonia: A Pragmatic Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29164170" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
